ProKidney financials
$1.63+1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $150.0K | $226.0K | $225.0K | $217.0K | $221.0K | $230.0K | $76.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $150.0K | $226.0K | $225.0K | $217.0K | $221.0K | $230.0K | $76.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating income | -$48.4M | -$44.9M | -$45.4M | -$38.5M | -$39.7M | -$41.4M | -$51.6M | -$49.0M | -$43.1M | -$40.1M | -$24.2M | -$46.6M |
| Net income | -$28.4M | -$20.0M | -$19.2M | -$16.5M | -$16.6M | -$16.7M | -$21.3M | -$17.9M | -$12.5M | -$9.5M | -$5.7M | -$11.0M |
| Net margin | −18948.0% | −8865.9% | −8547.1% | −7589.4% | −7489.6% | −7275.7% | −27997.4% | — | — | — | — | — |
| Diluted EPS | $-0.15 | $-0.14 | $-0.13 | $-0.12 | $-0.13 | $-0.13 | $-0.17 | $-0.14 | $-0.16 | $-0.16 | $-0.10 | $-0.18 |
| EBITDA | -$46.7M | -$43.3M | -$43.5M | -$36.9M | -$38.2M | -$39.8M | -$50.0M | -$47.5M | -$41.8M | -$39.0M | -$24.2M | -$45.6M |
| Operating cash flow | -$40.4M | -$41.7M | -$32.5M | -$26.6M | -$31.4M | -$29.6M | -$24.2M | -$29.2M | -$38.3M | -$34.6M | -$25.4M | -$23.8M |
| Free cash flow | -$44.2M | -$45.5M | -$38.3M | -$31.8M | -$34.5M | -$30.7M | -$49.7M | -$31.6M | -$38.9M | -$35.6M | -$27.0M | -$51.7M |
| Diluted shares | 186.6M | 141.9M | 143.1M | 135.0M | 130.7M | 127.0M | 128.6M | 126.2M | 75.9M | 61.0M | 59.2M | 61.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $74.9M | $101.9M | $108.5M | $95.3M | $84.9M | $97.8M |
| Short-term investments | $106.7M | $123.0M | $161.5M | $176.4M | $209.8M | $230.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $249.0M | $292.8M | $335.6M | $351.6M | $372.1M | $406.1M |
| Total liabilities | $26.2M | $29.7M | $34.8M | $33.3M | $32.7M | $36.1M |
| Shareholders' equity | -$883.5M | -$1.02B | -$1.01B | -$1.01B | -$1.00B | -$998.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology